Many people fear that a family history of dementia dooms them to inevitably suffer the condition themselves. But a new tool, ...

A Colombian man carried one of the most aggressive genetic mutations known to cause early-onset Alzheimer’s disease. By all ...

AUVELITY is a first-in-class treatment, which targets the NMDA and sigma-1 receptors, approved for agitation associated with dementia due to ...

Alzheimer’s disease and other forms of dementia affect millions of people across the globe. The organization Alzheimer’s Disease ...

An earlier diagnosis and intervention strategy for Alzheimer's disease is on the horizon, signaling a need to overhaul current detection methods and patient care protocols, experts at the Alzheimer's ...

Four years after gaining FDA approval for Auvelity to treat major depressive disorder (MDD), Axsome Therapeutics has tacked ...

Diet, gut health, cardiovascular conditions and surgical history were identified as the most prevalent drivers of Alzheimer’s ...

The Food and Drug Administration (FDA) approved the drug Auvelity this week for the treatment of agitation in adults with ...

Subtle biological changes linked to Alzheimer's disease may begin as early as the late 50s—decades before memory loss or ...

Oral NMDA receptor antagonist gets an expanded indication ...

Scientists from Johns Hopkins Medicine report new evidence that clusters of brain tissue derived from the cells of patients ...